These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 29080382)
21. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Veldman A; Hoffman M; Ehrenforth S Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684 [TBL] [Abstract][Full Text] [Related]
22. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848 [TBL] [Abstract][Full Text] [Related]
23. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. Hethershaw EL; Cilia La Corte AL; Duval C; Ali M; Grant PJ; Ariëns RA; Philippou H J Thromb Haemost; 2014 Feb; 12(2):197-205. PubMed ID: 24261582 [TBL] [Abstract][Full Text] [Related]
24. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536 [TBL] [Abstract][Full Text] [Related]
25. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Hevessy Z; Haramura G; Boda Z; Udvardy M; Muszbek L Thromb Haemost; 1996 Jan; 75(1):161-7. PubMed ID: 8713796 [TBL] [Abstract][Full Text] [Related]
26. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Carr ME; Martin EJ; Kuhn JG; Seremetis SV Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776 [TBL] [Abstract][Full Text] [Related]
27. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Shima M Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433 [TBL] [Abstract][Full Text] [Related]
28. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Dickneite G; Herwald H; Korte W; Allanore Y; Denton CP; Matucci Cerinic M Thromb Haemost; 2015 Apr; 113(4):686-97. PubMed ID: 25652913 [TBL] [Abstract][Full Text] [Related]
29. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408 [TBL] [Abstract][Full Text] [Related]
30. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. Holmberg HL; Lauritzen B; Tranholm M; Ezban M J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792 [TBL] [Abstract][Full Text] [Related]
31. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice. Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350 [TBL] [Abstract][Full Text] [Related]
33. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. Duan X; Tang M; Zhang J; Yu H; Xu R Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429 [TBL] [Abstract][Full Text] [Related]
34. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323 [TBL] [Abstract][Full Text] [Related]
35. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A. Girard TJ; Lasky NM; Grunz K; Broze GJ J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376 [TBL] [Abstract][Full Text] [Related]
36. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B. Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555 [TBL] [Abstract][Full Text] [Related]
37. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406 [TBL] [Abstract][Full Text] [Related]
38. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. Livnat T; Budnik I; Levy-Mendelovich S; Avishai E; Misgav M; Barg AA; Lubetsky A; Brutman-Barazani T; Kenet G Blood Cells Mol Dis; 2017 Jul; 66():1-5. PubMed ID: 28689155 [TBL] [Abstract][Full Text] [Related]
39. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. Radtke KP; Griffin JH; Riceberg J; Gale AJ J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431 [TBL] [Abstract][Full Text] [Related]